<code id='EEDD50E124'></code><style id='EEDD50E124'></style>
    • <acronym id='EEDD50E124'></acronym>
      <center id='EEDD50E124'><center id='EEDD50E124'><tfoot id='EEDD50E124'></tfoot></center><abbr id='EEDD50E124'><dir id='EEDD50E124'><tfoot id='EEDD50E124'></tfoot><noframes id='EEDD50E124'>

    • <optgroup id='EEDD50E124'><strike id='EEDD50E124'><sup id='EEDD50E124'></sup></strike><code id='EEDD50E124'></code></optgroup>
        1. <b id='EEDD50E124'><label id='EEDD50E124'><select id='EEDD50E124'><dt id='EEDD50E124'><span id='EEDD50E124'></span></dt></select></label></b><u id='EEDD50E124'></u>
          <i id='EEDD50E124'><strike id='EEDD50E124'><tt id='EEDD50E124'><pre id='EEDD50E124'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:hotspot    Page View:39125

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In